IQVIA (NYSE:IQV) Insider James Berkshire Sells 2,668 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider James Berkshire sold 2,668 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the transaction, the insider directly owned 10,890 shares of the company’s stock, valued at $2,845,883.70. The trade was a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

IQVIA Stock Down 1.6%

Shares of IQVIA stock opened at $267.34 on Friday. The company’s fifty day simple moving average is $230.54 and its two-hundred day simple moving average is $192.66. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $271.80. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market cap of $44.00 billion, a P/E ratio of 33.17, a PEG ratio of 2.32 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the prior year, the firm earned $2.81 earnings per share. IQVIA’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

Institutional Trading of IQVIA

Large investors have recently made changes to their positions in the stock. International Assets Investment Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at $27,000. Compass Financial Management LLC purchased a new position in IQVIA in the second quarter worth about $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA during the 4th quarter valued at about $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA during the 4th quarter valued at about $28,000. Finally, Financial Freedom LLC purchased a new stake in shares of IQVIA during the 1st quarter valued at about $25,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Mizuho lifted their price objective on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. TD Cowen raised their price target on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Robert W. Baird increased their price objective on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, Stifel Nicolaus lifted their target price on shares of IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $243.62.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.